Health Trials

REMIDEP-HTA Program for Hypertension Remission and Medication Deprescription

ConditionEssential Hypertension
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-65
SponsorEvelyn Vanina Re

About this trial

The REMIDEP-HTA trial is a multicenter randomized controlled study designed to evaluate whether a structured approach combining an intensive lifestyle intervention with a systematic deprescribing algorithm can achieve clinical remission of essential hypertension.

\<br\>\<br\>

The intervention integrates a 12-week high-intensity behavioral program focused on whole-food plant-based nutrition, progressive physical activity, sleep hygiene, and stress management, together with a hierarchical, safety-centered medication tapering protocol for antihypertensive therapy.

\<br\>\<br\>

The study aims to determine whether remission can be achieved through a standardized and monitored strategy that prioritizes clinical safety during medication withdrawal.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Intensive Lifestyle Intervention
  • Pharmacological Deprescribing Algorithm
  • Standard Medical Care

Treatment groups

240 Participants
are divided into 2 treatment groups

Locations

1

Map coordinates are unavailable for these locations. Locations are shown below instead.

Universidad Abierta Interamericana Status unavailable C1147AAU, Buenos Aires, Buenos AiresArgentinaArgentina

Sponsors and collaborators

Evelyn Vanina Re

Lead sponsor

Universidad Abierta Interamericana

Sponsor institution

Source ClinicalTrials.gov